

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study

In the article titled “Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study”, published on pages 148-155, Issue 2, Volume 16 of Journal of Human Reproductive Sciences,^[1] On page 151 Table 2 the heading for Group B (≥ 35 years), the sample size for the Gonal-f group and r-hFSH groups n values has been incorrectly mentioned as n=118 and n=166

The correct values should read as

The heading for Group B (≥ 35 years), the sample size for the Gonal-f group and r-hFSH groups as n=55 and n=23

The Table 2 footnote has been incorrectly mentioned as *Significant difference between the two groups, \$Embryos at cleavage/blastocyst stage, #The OR could not be calculated for miscarriage and LBR in case of Group B as in at least one case the value of the variable was zero. CI=Confidence interval, SD=Standard deviation, n=Number of patients, OR=Odds ratio, r-hFSH=Human recombinant follicle stimulating hormone, NA=Not available, LBR=Live birth rate

The correct Table 2 footnote should read as **Abbreviations:** CI, confidence interval; SD, standard deviation; n, number of patients; OR, odds ratio; r-hFSH, human recombinant follicle stimulating hormone

\$Embryos at cleavage/blastocyst stage

*Significant difference between the two groups. ** Percentages have been calculated based on number of patients considered for the particular outcome

#The odds ratio could not be calculated for miscarriage and live birth rate in case of Group B as in at least one case the value of the variable was zero

Incorrect Table 2

Table 2: Subgroup analysis of reproductive outcomes

Parameters	Group A (<35 years)				Group B (≥35 years)			
	Gonal-f® (n=118)	r-hFSH biosimilar (n=166)	P	OR (95% CI)	Gonal-f® (n=118)	r-hFSH biosimilar (n=166)	P	OR (95% CI)
Number of embryos [§] on day 6, mean±SD (95% CI)	3.7±2.5 (3.15–4.19)	4.4±3.0 (3.8–4.9)	0.158		3.2±2.2 (2.6–3.8)	5.7±4.3 (3.8–7.6)	0.012*	
Embryo transfers								
Cleavage-stage transfers	26 (22)	46 (27.7)			11 (20)	05 (21.7)		
Blastocyst-stage transfers	86 (72.8)	111 (66.9)			40 (72.7)	17 (74)		
Double transfers	3 (2.5)	3 (1.8)			3 (5.4)	0		
No transfers/cancelled transfers	3 (2.5)	6 (3.6)			1 (1.8)	1 (4.3)		
Number of embryos transferred [§] , mean±SD (95% CI)	3.0±2.8 (2.4–3.6)	2.0±0.6 (1.9–2.1)	0.001*		2.7±3.0 (1.9–3.5)	1.8±0.5 (1.6–2.0)	0.080	
Number of good quality embryos (cleavage/blastocyst)	5.1±2.9	4.8±3.1			4.6±3.3	6.1±4.3		
Number of patients, embryo [§] quality, n (%)								
Good	97 (82.2)	114 (68.7)			47 (85.4)	17 (73.9)		
Poor	21 (17.8)	50 (30.1)			8 (14.5)	6 (26.1)		
Clinical pregnancy rate (positive), n (%) (95% CI)	58 (59.2) (0.49–0.7)	54 (39.7) (0.3–0.5)	0.012*	2.2 (1.31–3.79)	35 (46.1) (0.4–0.6)	8 (14.8) (0.1–0.5)	0.046*	2.6 (1–6.75)
LBR (full term), n (%) (95% CI)	42 (43) (0.3–0.5)	24 (17.7) (0.1–0.3)	0.0001*	2.6 (0.41–16.83)	24 (31.6) (0.2–0.5)	5 (9.3) (0.1–0.4)	0.264	NA [#]
Miscarriage rate, n (%) (95% CI)	5 (9.8) (0.0–0.1)	10 (18.9) (0.0–0.1)	0.188	0.5 (0.15–1.48)	6 (7.9) (0.0–0.2)	0	0.187	NA [#]

*Significant difference between the two groups, [§]Embryos at cleavage/blastocyst stage, [#]The OR could not be calculated for miscarriage and LBR in case of Group B as in at least one case the value of the variable was zero. CI=Confidence interval, SD=Standard deviation, n=Number of patients, OR=Odds ratio, r-hFSH=Human recombinant follicle stimulating hormone, NA=Not available, LBR=Live birth rate

Corrected Table 2

Parameters	Group A (< 35 years)			OR [95% CI]	Group B (≥ 35 years)			OR [95% CI]
	Gonal-f® (n=118)	r-hFSH biosimilar (n=166)	P		Gonal-f® (n=55)	r-hFSH biosimilar (n=23)	P	
Number of embryos ^s on Day 6 (mean±SD) [95% CI]	3.7±2.5 [3.15-4.19]	4.4±3.0 [3.8-4.9]	0.158		3.2±2.2 [2.6-3.8]	5.7±4.3 [3.8-7.6]	0.012*	
Embryo transfers								
Cleavage-stage transfers	26 (22%)	46 (27.7%)			11 (20%)	05 (21.7%)		
Blastocyst-stage transfers	86 (72.8%)	111 (66.9%)			40 (72.7%)	17 (74%)		
Double transfers	03 (2.5%)	03 (1.8%)			03 (5.4%)	0		
No transfers/Cancelled transfers	03 (2.5%)	06 (3.6%)			01 (1.8%)	01 (4.3%)		
Number of embryos transferred ^s (mean±SD) [95% CI]	3.0±2.8 [2.4-3.6]	2.0±0.6 [1.9-2.1]	0.001*		2.7±3.0 [1.9-3.5]	1.8±0.5 [1.6-2.0]	0.080	
Number of good quality embryos (cleavage/blastocyst)	5.1±2.9	4.8±3.1			4.6±3.3	6.1±4.3		
Number of patients, embryo ^s quality, n (%)								
Good	97 (82.2%)	114 (68.7%)			47 (85.4%)	17 (73.9%)		
Poor	21 (17.8%)	50 (30.1%)			08 (14.5%)	06 (26.1%)		
Clinical pregnancy rate (positive), n (%) [95% CI]**	58 (59.2%) [0.49-0.7]	54 (39.7%) [0.3-0.5]	0.012*	2.2 [1.31-3.79]	35 (46.1%) [0.4-0.6]	8 (14.8%) [0.1-0.5]	0.046*	2.6 [1-6.75]
Live birth rate (full term), n (%) [95% CI]**	42 (43%) [0.3-0.5]	24 (17.7%) [0.1-0.3]	0.0001*	2.6 [0.41-16.83]	24 (31.6%) [0.2-0.5]	5 (9.3%) [0.1-0.4]	0.264	NA [#]
Miscarriage rate n (%) [95% CI]**	5 (9.8%) [0.0-0.1]	10 (18.9%) [0.0-0.1]	0.188	0.5 [0.15-1.48]	6 (7.9%) [0.0-0.2]	0 (0%)	0.187	NA [#]

CI, confidence interval; SD, standard deviation; n, number of patients; OR, odds ratio; r-hFSH, human recombinant follicle stimulating hormone. ^sEmbryos at cleavage/blastocyst stage. *Significant difference between the two groups. **Percentages have been calculated based on number of patients considered for the particular outcome. [#]The odds ratio could not be calculated for miscarriage and live birth rate in case of Group B as in at least one case the value of the variable was zero

On page 152 under Discussion section, paragraph 2 the sentence has been incorrectly mentioned as Currently, several licensed biosimilars for follitropin such as Ovaleap®, Bemfola®, Pergoveris®, Primapur®, Follitrope®, Elonva®, Rekovelle® and Clinnal-f® are being used across the world in clinical settings.

The correct sentence should read as

Currently, licensed biosimilars for follitropin such as Ovaleap®, Bemfola®, and Primapur® are being used across the world in clinical settings.

REFERENCE

1. Patel NH, Patel NH, Patel MN, Bhadarka HK, Vyas KS. Clinical outcomes in patients receiving originator follitropin alfa and follitropin alfa biosimilars in real-world clinical practice: A retrospective study. J Hum Reprod Sci 2023;16:148-55.

DOI: 10.4103/0974-1208.386502